B-intervention	0	6	Manual
I-intervention	7	12	lymph
I-intervention	13	21	drainage
O	22	26	when
O	27	32	added
O	33	35	to
O	36	42	advice
O	43	46	and
O	47	55	exercise
O	56	59	may
O	60	63	not
O	64	66	be
O	67	76	effective
O	77	79	in
O	80	90	preventing
B-condition	91	102	lymphoedema
O	103	108	after
O	109	116	surgery
O	117	120	for
O	121	127	breast
O	128	134	cancer
O	134	135	.

O	136	143	Summary
O	144	146	of
O	146	147	:
O	148	156	Devoogdt
O	157	158	N
O	159	161	et
O	162	164	al
O	165	166	(
O	166	170	2011
O	170	171	)
O	172	178	Effect
O	179	181	of
O	182	188	manual
O	189	194	lymph
O	195	203	drainage
O	204	206	in
O	207	215	addition
O	216	218	to
O	219	229	guidelines
O	230	233	and
O	234	242	exercise
O	243	250	therapy
O	251	253	on
O	254	257	arm
O	258	269	lymphoedema
O	270	277	related
O	278	280	to
O	281	287	breast
O	288	294	cancer
O	294	295	:
O	296	306	randomized
O	307	317	controlled
O	318	323	trial
O	323	324	.

O	325	328	BMJ
O	329	332	343
O	332	333	:
O	334	339	d5326
O	339	340	.

O	341	342	[
O	342	350	Prepared
O	351	353	by
O	354	362	Nicholas
O	363	369	Taylor
O	369	370	,
O	371	374	CAP
O	375	381	Editor
O	381	382	.
O	382	383	]
O	384	388	Does
O	389	395	manual
O	396	401	lymph
O	402	410	drainage
O	411	418	prevent
O	419	430	lymphoedema
O	431	433	in
O	434	442	patients
O	443	446	who
O	447	451	have
O	452	455	had
O	456	463	surgery
O	464	467	for
O	468	474	breast
O	475	481	cancer
O	481	482	?
O	482	483	.

O	484	494	Randomised
O	494	495	,
O	496	506	controlled
O	507	512	trial
O	513	517	with
O	518	527	concealed
O	528	538	allocation
O	539	542	and
O	543	550	blinded
O	551	558	outcome
O	559	569	assessment
O	569	570	.

O	571	572	A
O	573	590	multidisciplinary
O	591	597	breast
O	598	604	centre
O	605	607	of
O	608	609	a
O	610	618	tertiary
O	619	627	hospital
O	628	630	in
B-location	631	638	Belgium
O	638	639	.

O	640	648	Patients
O	649	653	were
O	654	662	eligible
O	663	665	to
O	666	668	be
O	669	677	included
O	678	680	if
B-eligibility	681	685	they
I-eligibility	686	694	received
I-eligibility	695	705	unilateral
I-eligibility	706	713	surgery
I-eligibility	714	718	with
I-eligibility	719	727	axillary
I-eligibility	728	732	node
I-eligibility	733	743	dissection
I-eligibility	744	747	for
I-eligibility	748	754	breast
I-eligibility	755	761	cancer
O	761	762	,
O	763	766	and
O	767	773	agreed
O	774	776	to
O	777	788	participate
O	788	789	.

O	790	803	Randomisation
O	804	806	of
B-total-participants	807	810	160
O	811	823	participants
O	824	833	allocated
B-intervention-participants	834	836	79
O	837	839	to
O	840	843	the
O	844	856	intervention
O	857	862	group
O	863	866	and
B-control-participants	867	869	81
O	870	872	to
O	873	874	a
B-control	875	882	control
I-control	883	888	group
O	888	889	.

O	890	894	Both
O	895	901	groups
O	902	910	received
O	911	921	guidelines
O	922	927	about
O	928	931	the
O	932	942	prevention
O	943	945	of
O	946	957	lymphoedema
O	958	960	in
O	961	964	the
O	965	969	form
O	970	972	of
O	973	974	a
O	975	983	brochure
O	983	984	,
O	985	988	and
O	989	997	exercise
O	998	1005	therapy
O	1006	1015	involving
O	1016	1026	supervised
O	1027	1041	individualised
O	1042	1044	30
O	1045	1051	minute
O	1052	1060	sessions
O	1061	1062	-
O	1063	1072	initially
O	1073	1078	twice
O	1079	1080	a
O	1081	1085	week
O	1085	1086	,
O	1087	1095	reducing
O	1096	1098	to
O	1099	1103	once
O	1104	1115	fortnightly
O	1116	1118	as
O	1119	1127	patients
O	1128	1138	progressed
O	1138	1139	.

O	1140	1152	Participants
O	1153	1155	in
O	1156	1160	both
O	1161	1167	groups
O	1168	1172	were
O	1173	1177	also
O	1178	1183	asked
O	1184	1186	to
O	1187	1194	perform
O	1195	1204	exercises
O	1205	1207	at
O	1208	1212	home
O	1213	1218	twice
O	1218	1219	/
O	1219	1222	day
O	1222	1223	.

O	1224	1226	In
O	1227	1235	addition
O	1235	1236	,
O	1237	1240	the
O	1241	1253	intervention
O	1254	1259	group
O	1260	1268	received
O	1269	1271	40
O	1272	1280	sessions
O	1281	1283	of
O	1284	1290	manual
O	1291	1296	lymph
O	1297	1305	drainage
O	1306	1310	over
O	1311	1313	20
O	1314	1319	weeks
O	1320	1324	with
O	1325	1329	each
O	1330	1337	session
O	1338	1345	lasting
O	1346	1348	30
O	1349	1356	minutes
O	1357	1360	and
O	1361	1370	performed
O	1371	1373	by
O	1374	1381	trained
O	1382	1392	therapists
O	1392	1393	.

O	1394	1397	The
O	1398	1405	primary
O	1406	1414	outcomes
O	1415	1419	were
O	1420	1423	the
B-outcome-Measure	1424	1434	cumulative
I-outcome-Measure	1435	1444	incidence
I-outcome-Measure	1445	1447	of
I-outcome-Measure	1448	1451	and
I-outcome-Measure	1452	1455	the
I-outcome-Measure	1456	1460	time
I-outcome-Measure	1461	1463	to
I-outcome-Measure	1464	1471	develop
I-outcome-Measure	1472	1475	arm
I-outcome-Measure	1476	1487	lymphoedema
O	1488	1489	(
O	1489	1496	defined
O	1497	1499	as
O	1500	1501	a
O	1502	1505	200
O	1506	1508	ml
O	1509	1517	increase
O	1517	1518	)
O	1519	1521	as
O	1522	1530	measured
O	1531	1535	with
O	1536	1539	the
O	1540	1545	water
O	1546	1558	displacement
O	1559	1565	method
O	1566	1570	with
O	1571	1579	measures
O	1580	1585	taken
O	1586	1588	at
O	1589	1597	baseline
O	1598	1601	and
O	1602	1603	1
O	1603	1604	,
O	1605	1606	3
O	1606	1607	,
O	1608	1609	6
O	1609	1610	,
O	1611	1614	and
O	1615	1617	12
O	1618	1624	months
O	1625	1630	after
O	1631	1638	surgery
O	1638	1639	.

O	1640	1649	Secondary
O	1650	1657	outcome
O	1658	1666	measures
O	1667	1671	were
B-outcome-Measure	1672	1683	lymphoedema
O	1684	1692	measured
O	1693	1697	with
O	1698	1701	the
O	1702	1705	arm
O	1706	1719	circumference
O	1720	1726	method
O	1726	1727	,
B-outcome-Measure	1728	1734	health
I-outcome-Measure	1734	1735	-
I-outcome-Measure	1735	1742	related
I-outcome-Measure	1743	1750	quality
I-outcome-Measure	1751	1753	of
I-outcome-Measure	1754	1758	life
I-outcome-Measure	1759	1764	using
I-outcome-Measure	1765	1768	the
I-outcome-Measure	1769	1771	SF
I-outcome-Measure	1771	1772	-
I-outcome-Measure	1772	1774	36
I-outcome-Measure	1775	1780	scale
O	1780	1781	,
O	1782	1785	and
O	1786	1787	a
B-outcome-Measure	1788	1795	patient
I-outcome-Measure	1796	1804	reported
I-outcome-Measure	1805	1818	questionnaire
O	1819	1821	to
O	1822	1827	score
O	1828	1831	the
O	1832	1840	presence
O	1841	1843	of
O	1844	1854	subjective
O	1855	1858	arm
O	1859	1870	lymphoedema
O	1870	1871	.

B-total-participants	1872	1875	154
O	1876	1888	participants
O	1889	1890	(
O	1890	1892	96
O	1892	1893	%
O	1893	1894	)
O	1895	1904	completed
O	1905	1908	the
O	1909	1914	study
O	1915	1917	at
O	1918	1920	12
O	1921	1927	months
O	1927	1928	.

O	1929	1931	At
O	1932	1934	12
O	1935	1941	months
O	1942	1945	the
B-outcome	1946	1955	incidence
I-outcome	1956	1958	of
I-outcome	1959	1970	lymphoedema
O	1971	1973	in
O	1974	1977	the
O	1978	1990	intervention
O	1991	1996	group
O	1997	1998	(
O	1998	1999	n
O	1999	2000	=
B-iv-bin-abs	2000	2002	18
O	2002	2003	,
B-iv-bin-percent	2004	2006	24
I-iv-bin-percent	2006	2007	%
O	2007	2008	)
O	2009	2012	was
O	2013	2020	similar
O	2021	2023	to
O	2024	2027	the
O	2028	2037	incidence
O	2038	2040	of
O	2041	2052	lymphoedema
O	2053	2055	in
O	2056	2059	the
O	2060	2067	control
O	2068	2073	group
O	2074	2075	(
O	2075	2076	n
O	2077	2078	=
B-cv-bin-abs	2079	2081	15
O	2081	2082	,
B-cv-bin-percent	2083	2085	19
I-cv-bin-percent	2085	2086	%
O	2086	2087	,
O	2088	2090	OR
O	2091	2092	1
O	2092	2093	.
O	2093	2094	3
O	2094	2095	,
O	2096	2098	95
O	2098	2099	%
O	2100	2102	CI
O	2103	2104	0
O	2104	2105	.
O	2105	2106	6
O	2107	2109	to
O	2110	2111	2
O	2111	2112	.
O	2112	2113	4
O	2113	2114	)
O	2114	2115	;
O	2116	2120	also
O	2121	2126	there
O	2127	2130	was
O	2131	2133	no
O	2134	2144	difference
O	2145	2147	in
O	2148	2157	incidence
O	2158	2160	at
O	2161	2162	3
O	2163	2165	or
O	2166	2167	6
O	2168	2174	months
O	2174	2175	.

O	2176	2181	There
O	2182	2185	was
O	2186	2188	no
O	2189	2199	difference
O	2200	2207	between
O	2208	2211	the
O	2212	2218	groups
O	2219	2221	in
O	2222	2225	the
B-outcome	2226	2230	time
I-outcome	2231	2236	taken
I-outcome	2237	2239	to
I-outcome	2240	2247	develop
I-outcome	2248	2259	lymphoedema
O	2259	2260	,
O	2261	2264	and
O	2265	2267	no
O	2268	2278	difference
O	2279	2286	between
O	2287	2290	the
O	2291	2297	groups
O	2298	2300	in
O	2301	2304	any
O	2305	2314	secondary
O	2315	2322	outcome
O	2323	2330	measure
O	2330	2331	.

O	2332	2335	The
O	2336	2347	application
O	2348	2350	of
O	2351	2357	manual
O	2358	2363	lymph
O	2364	2372	drainage
O	2373	2378	after
O	2379	2387	axillary
O	2388	2392	node
O	2393	2403	dissection
O	2404	2407	for
O	2408	2414	breast
O	2415	2421	cancer
O	2422	2424	in
O	2425	2433	addition
O	2434	2436	to
O	2437	2446	providing
O	2447	2457	guidelines
O	2458	2461	and
O	2462	2470	exercise
O	2471	2478	therapy
O	2479	2482	did
O	2483	2486	not
O	2487	2494	prevent
O	2495	2506	lymphoedema
O	2507	2509	in
O	2510	2513	the
O	2514	2519	first
O	2520	2524	year
O	2525	2530	after
O	2531	2538	surgery
O	2538	2539	.
